To investigate tumorigenesis in the context of a minimum complement of pathway alterations, we employed transgenic expression of the HPV16 E6-E7 oncogenes21, which inhibit TP53 and CDKN2A tumor suppressors, and the constitutively active YAP1S127A allele22. The gene discussed is CDKN2A; the disease is neoplasm.